22.64
price down icon0.66%   -0.15
after-market After Hours: 22.64
loading
Nurix Therapeutics Inc stock is traded at $22.64, with a volume of 648.94K. It is down -0.66% in the last 24 hours and down -9.62% over the past month. Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
See More
Previous Close:
$22.79
Open:
$22.57
24h Volume:
648.94K
Relative Volume:
0.84
Market Cap:
$1.60B
Revenue:
$80.89M
Net Income/Loss:
$-144.73M
P/E Ratio:
-7.6229
EPS:
-2.97
Net Cash Flow:
$-83.87M
1W Performance:
-16.61%
1M Performance:
-9.62%
6M Performance:
+39.84%
1Y Performance:
+247.77%
1-Day Range:
Value
$21.88
$22.88
1-Week Range:
Value
$20.65
$27.53
52-Week Range:
Value
$5.65
$29.56

Nurix Therapeutics Inc Stock (NRIX) Company Profile

Name
Name
Nurix Therapeutics Inc
Name
Phone
(415) 660-5320
Name
Address
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Name
Employee
284
Name
Twitter
Name
Next Earnings Date
2024-10-14
Name
Latest SEC Filings
Name
NRIX's Discussions on Twitter

Compare NRIX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
NRIX 22.64 1.60B 80.89M -144.73M -83.87M -2.97
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-31-24 Initiated Truist Buy
Jun-26-23 Resumed Oppenheimer Outperform
Mar-09-23 Initiated Barclays Overweight
Feb-28-23 Initiated Oppenheimer Outperform
Oct-11-22 Initiated Morgan Stanley Equal-Weight
May-31-22 Upgrade Wells Fargo Equal Weight → Overweight
Feb-10-22 Initiated Wells Fargo Equal Weight
Dec-29-21 Initiated H.C. Wainwright Buy
Oct-14-21 Initiated SVB Leerink Outperform
Jun-04-21 Resumed Robert W. Baird Outperform
Apr-30-21 Resumed Piper Sandler Overweight
Apr-30-21 Initiated RBC Capital Mkts Outperform
Apr-14-21 Initiated Berenberg Buy
Nov-19-20 Initiated Robert W. Baird Outperform
Aug-18-20 Initiated JP Morgan Overweight
Aug-18-20 Initiated Needham Buy
Aug-18-20 Initiated Piper Sandler Overweight
Aug-18-20 Initiated Stifel Buy
View All

Nurix Therapeutics Inc Stock (NRIX) Latest News

pulisher
Nov 20, 2024

Nurix Therapeutics Receives PRIME Designation from the - GlobeNewswire

Nov 20, 2024
pulisher
Nov 20, 2024

Nurix's Cancer Drug NX-5948 Secures EMA PRIME Status for Advanced Leukemia Treatment | NRIX Stock News - StockTitan

Nov 20, 2024
pulisher
Nov 19, 2024

Amalgamated Bank Has $49,000 Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World

Nov 19, 2024
pulisher
Nov 18, 2024

Nurix Therapeutics (NASDAQ:NRIX) Shares Gap DownShould You Sell? - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Sumitomo Mitsui Trust Group Inc. Purchases New Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Nov 18, 2024
pulisher
Nov 17, 2024

Chevron Corp (CVX-N) QuotePress Release - The Globe and Mail

Nov 17, 2024
pulisher
Nov 17, 2024

Mplx LP (MPLX-N) QuotePress Release - The Globe and Mail

Nov 17, 2024
pulisher
Nov 17, 2024

Nurix Therapeutics Presents Preclinical Data from Two - GlobeNewswire

Nov 17, 2024
pulisher
Nov 17, 2024

Nurix Reports Strong Preclinical Data for Two Novel Autoimmune Disease Treatments | NRIX Stock News - StockTitan

Nov 17, 2024
pulisher
Nov 15, 2024

Nurix Therapeutics (NASDAQ:NRIX) Shares Down 8.7%Should You Sell? - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Redmile Group, LLC Expands Stake in Nurix Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Significant Stake Increase by Baker Bros. Advisors in Nurix Ther - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

WASATCH ADVISORS LP Adjusts Stake in Nurix Therapeutics Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

When the Price of (NRIX) Talks, People Listen - Stock Traders Daily

Nov 14, 2024
pulisher
Nov 13, 2024

Conocophillips (COP-N) QuotePress Release - The Globe and Mail

Nov 13, 2024
pulisher
Nov 08, 2024

Wellington Management Group LLP Increases Stake in Nurix Therape - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Purchased by International Assets Investment Management LLC - Defense World

Nov 08, 2024
pulisher
Nov 08, 2024

ARK Investment Management LLC Has $49.80 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Nurix Therapeutics stock soars to 52-week high of $27.61 By Investing.com - Investing.com Canada

Nov 08, 2024
pulisher
Nov 07, 2024

Morgan Stanley's Strategic Reduction in Nurix Therapeutics Holdi - GuruFocus.com

Nov 07, 2024
pulisher
Nov 07, 2024

Nurix Therapeutics (NASDAQ:NRIX) Hits New 1-Year HighHere's Why - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Nurix Therapeutics stock soars to 52-week high of $27.61 - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25% - Simply Wall St

Nov 07, 2024
pulisher
Nov 07, 2024

Cisco Systems Inc (CSCO-Q) QuotePress Release - The Globe and Mail

Nov 07, 2024
pulisher
Nov 06, 2024

The Analyst Verdict: Nurix Therapeutics In The Eyes Of 10 Experts - Benzinga

Nov 06, 2024
pulisher
Nov 06, 2024

Nurix Therapeutics' (NRIX) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

Nurix therapeutics' chief legal officer sells $82,250 in stock - Investing.com India

Nov 05, 2024
pulisher
Nov 05, 2024

SEC Form 424B5 filed by Nurix Therapeutics Inc. - Quantisnow

Nov 05, 2024
pulisher
Nov 04, 2024

Nurix therapeutics' chief legal officer sells $82,250 in stock By Investing.com - Investing.com UK

Nov 04, 2024
pulisher
Nov 03, 2024

(NRIX) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 03, 2024
pulisher
Nov 02, 2024

Nurix therapeutics CFO Hans van Houte sells $86,083 in stock - Investing.com India

Nov 02, 2024
pulisher
Nov 02, 2024

Houte Hans Van Sells 3,546 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Nurix therapeutics CFO Hans van Houte sells $86,083 in stock By Investing.com - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Nurix therapeutics chief legal officer sells $139,866 in stock By Investing.com - Investing.com South Africa

Nov 01, 2024
pulisher
Nov 01, 2024

Nurix therapeutics chief legal officer sells $139,866 in stock - Investing.com India

Nov 01, 2024
pulisher
Nov 01, 2024

Insider Sale: CFO Houte Van Sells Shares of Nurix Therapeutics I - GuruFocus.com

Nov 01, 2024
pulisher
Oct 31, 2024

Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Oct 31, 2024
pulisher
Oct 31, 2024

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth - Simply Wall St

Oct 31, 2024
pulisher
Oct 31, 2024

Nurix therapeutics chief scientific officer sells shares worth $83,536 By Investing.com - Investing.com Australia

Oct 31, 2024
pulisher
Oct 30, 2024

Nurix therapeutics chief legal officer sells shares worth over $101k By Investing.com - Investing.com South Africa

Oct 30, 2024
pulisher
Oct 30, 2024

Nurix therapeutics chief scientific officer sells shares worth $83,536 - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

Nurix therapeutics chief legal officer sells shares worth over $101k - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

Nurix therapeutics CFO Hans van Houte sells $57,554 in stock - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

Nurix therapeutics CFO Hans van Houte sells $57,554 in stock By Investing.com - Investing.com Australia

Oct 30, 2024
pulisher
Oct 30, 2024

Allspring Global Investments Holdings LLC Makes New Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Allspring Global Investments Holdings LLC Makes New $3.15 Million Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World

Oct 30, 2024
pulisher
Oct 29, 2024

Magna International Inc (MG-T) QuotePress Release - The Globe and Mail

Oct 29, 2024
pulisher
Oct 28, 2024

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Oct 28, 2024
pulisher
Oct 26, 2024

Nurix Therapeutics stock soars to 52-week high of $26.46 By Investing.com - Investing.com Canada

Oct 26, 2024
pulisher
Oct 26, 2024

Nurix Therapeutics (NASDAQ:NRIX) Now Covered by UBS Group - Defense World

Oct 26, 2024

Nurix Therapeutics Inc Stock (NRIX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):